Experiment Protocol Biomedical Engineer in Malaysia Kuala Lumpur –Free Word Template Download with AI

Protocol ID: KL-BME-2023-004

Location: University Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia

Principal Investigator: Lead Biomedical Engineer, Department of Medical Physics

Date: October 24, 2023

Status: Approved for Implementation

This Experiment Protocol outlines the rigorous procedures required for the clinical validation of a novel wearable hemodynamic monitoring device. The study is conducted within the jurisdiction of Malaysia Kuala Lumpur, specifically leveraging the advanced medical infrastructure available in the capital city. The primary objective is to assess the accuracy, reliability, and safety of the device when used on diverse patient demographics typical of the region.

The Biomedical Engineer leading this study is responsible for ensuring that the device meets international standards (ISO 13485) as well as local regulatory requirements set by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. This protocol serves as the definitive guide for all technical and clinical personnel involved in the data acquisition and analysis phases.

The specific objectives of this experiment are:

• To validate the accuracy of continuous blood pressure monitoring against standard invasive arterial lines.
• To evaluate the device's performance under high-humidity conditions prevalent in Malaysia Kuala Lumpur.
• To ensure the Biomedical Engineer can successfully calibrate the device in a live clinical environment without disrupting patient care.
• To collect data necessary for regulatory submission to the Ministry of Health Malaysia.

This study will be conducted in the Intensive Care Unit (ICU) of a tertiary hospital in Kuala Lumpur. The study design is a prospective, observational, single-center trial. The Experiment Protocol mandates a sample size of 50 adult patients admitted for critical care, ensuring a statistically significant dataset.

The Biomedical Engineer will oversee the technical setup, ensuring that all sensors are applied correctly and that data transmission to the central monitoring station is secure and uninterrupted. The protocol strictly adheres to the Declaration of Helsinki and local ethical guidelines.

Category	Criteria
Inclusion	Age 18-75 years. Admitted to ICU in Kuala Lumpur for at least 48 hours. Requires continuous hemodynamic monitoring. Written informed consent obtained from patient or legal guardian.
Exclusion	Severe skin conditions at the sensor site. Pregnancy. Known allergy to adhesive materials. Patients with arrhythmias that may interfere with signal processing.

5.1 Device Preparation

Before patient interaction, the Biomedical Engineer must perform a comprehensive quality assurance check on the wearable device. This includes battery life verification, sensor calibration, and software integrity checks. All equipment must be sterilized according to the hospital's infection control protocols, which are stringent in Malaysia Kuala Lumpur healthcare facilities.

5.2 Data Acquisition

Once the device is applied to the patient, data will be recorded continuously for a period of 24 hours. The Experiment Protocol requires simultaneous recording using a gold-standard invasive arterial line to serve as the reference measurement. The Biomedical Engineer will monitor the data stream in real-time to identify any artifacts or signal loss.

Data synchronization is critical. The engineer must ensure that timestamps on both the wearable device and the hospital's central monitoring system are aligned to within one second of accuracy.

5.3 Environmental Considerations

Given the tropical climate of Malaysia Kuala Lumpur, the protocol includes specific checks for device performance under high humidity (average 80-90%). The Biomedical Engineer will document any instances of sensor detachment or signal degradation attributable to sweat or moisture, as this is a key variable in the study.

Patient safety is paramount. The Experiment Protocol outlines the following safety measures:

• Immediate removal of the device if skin irritation occurs.
• Continuous monitoring by nursing staff to ensure patient comfort.
• The Biomedical Engineer must be on-call during the data acquisition period to address any technical failures immediately.
• All data must be anonymized to protect patient privacy in compliance with the Personal Data Protection Act 2010 of Malaysia.

Upon completion of the data collection phase, the Biomedical Engineer will collaborate with clinical statisticians to analyze the results. The analysis will focus on:

• Mean absolute error between the wearable device and the invasive arterial line.
• Correlation coefficients (Pearson's r) for systolic and diastolic blood pressure readings.
• Incidence of technical failures or data loss.

The results will be compiled into a comprehensive report suitable for submission to the Medical Device Authority (MDA) in Malaysia Kuala Lumpur.

The Biomedical Engineer is the central figure in this Experiment Protocol. Their responsibilities include:

• Technical oversight of all equipment.
• Training nursing staff on device application and removal.
• Troubleshooting hardware and software issues.
• Ensuring compliance with all regulatory standards in Malaysia Kuala Lumpur.

This Experiment Protocol provides a structured approach to validating a new biomedical device in a real-world clinical setting. By adhering to these guidelines, the Biomedical Engineer ensures that the study yields reliable, reproducible, and ethically sound data. The successful completion of this protocol will contribute significantly to the advancement of medical technology in Malaysia Kuala Lumpur and potentially improve patient outcomes in critical care settings.

Principal Investigator:

Signature

Name: Dr. Ahmad Razak

Title: Senior Biomedical Engineer

Ethics Committee Chair:

Signature

Name: Prof. Sarah Lim

Title: Chair, Medical Ethics Committee

⬇️ Download as DOCX Edit online as DOCX